SUBSCRIBE
SUBSCRIBE

Phase 2

BioForest
Clinical Catch-Up: September 14-18
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
September 18, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study
Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.
September 18, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: September 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
September 17, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Jonathan Weiss/Shutterstock
Drug Development
Eli Lilly’s Antibody Therapy Against COVID-19 Reduced Hospitalization Rates
Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19.
September 16, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
September 16, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
September 14, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: September 7-11
It was a busy week for clinical trial updates. Here’s a look.
September 11, 2020
 · 
10 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: September 11
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
September 10, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Preclinical Data Supports Efficacy for Pfizer, BioNTech Phase II/III COVID-19 Vaccine
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
September 9, 2020
 · 
3 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: September 9
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
September 8, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Press Releases
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
July 3, 2026
 · 
6 min read
Press Releases
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
July 2, 2026
 · 
11 min read
Press Releases
Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
July 2, 2026
 · 
3 min read
Press Releases
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
July 1, 2026
 · 
4 min read
Press Releases
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
July 1, 2026
 · 
10 min read
Press Releases
AOB Pharma and Biorasi to Partner to run Phase 2b in Moderate to Severe Acne
July 1, 2026
 · 
4 min read
Press Releases
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
July 1, 2026
 · 
10 min read
Press Releases
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
July 1, 2026
 · 
7 min read
Press Releases
Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson’s Disease
June 30, 2026
 · 
3 min read
Press Releases
OTR4132 in patients with ischemic stroke meets primary efficacy endpoint
June 30, 2026
 · 
1 min read
Press Releases
OS Therapies Provides U.S. Regulatory Update
June 30, 2026
 · 
1 min read
Press Releases
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
June 30, 2026
 · 
9 min read
Press Releases
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026
 · 
4 min read
Press Releases
Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
June 30, 2026
 · 
6 min read
Press Releases
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
June 30, 2026
 · 
5 min read
Press Releases
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
June 30, 2026
 · 
8 min read
Press Releases
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
June 29, 2026
 · 
6 min read
Press Releases
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
June 29, 2026
 · 
6 min read
Press Releases
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
June 29, 2026
 · 
7 min read
Press Releases
TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New Immune Tolerance Approach in Kidney Transplantation
June 29, 2026
 · 
1 min read
Load More